Pathway to Cures (P2C) is a venture philanthropy fund created specifically to accelerate the development of cures across all inheritable blood and bleeding disorders. As a flexible partner working collaboratively with other organizations, P2C makes investments in innovative therapies and technologies, leveraging the deep resources and scientific community relationships of the National Bleeding Disorders Foundation (NBDF). By reinvesting proceeds from investments back into the Fund, P2C will amplify our impact by supporting the progress of promising companies and building a deep and diverse portfolio of investments that further our mission.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 1230 Avenue Of The Americas,
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- https://www.pathwaytocures.org/
- HQ
- New York, NY
Pathway To Cures Questions
Pathway To Cures's website is https://www.pathwaytocures.org/
Pathway To Cures's LinkedIn profile is https://www.linkedin.com/company/pathway-to-cures
Pathway To Cures has
4 employees.
View email and phone details for 4
employees at Pathway To Cures.
Pathway To Cures's industry is
Venture Capital and Private Equity Principals
Pathway To Cures's top competitors are
Royalty Pharma,
American Society Of Hematology,
Hemophilia News Today,
Bend Bioscience,
Sixty8 Capital,
Wave Ventures,
Symbol Capital, Llc,
Partners Physician Academy,
National Bleeding Disorders Foundation,
Spark Biomedical Inc.
Pathway To Cures's categories are Venture Capital and Private Equity Principals
Pathway To Cures's founding year is 2022
